Asset Management Group’s Xeris Biopharma Holdings XERS Stock Holding History

Asset Management Group’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$210K	Hold	26,480	–	–	0.03%	134
2026 Q1	$154K	Hold	26,480	–	–	0.02%	137
2025 Q4	$208K	Hold	26,480	–	–	0.03%	135
2025 Q3	$216K	Hold	26,480	–	–	0.04%	134
2025 Q2	$124K	Hold	26,480	–	–	0.02%	134
2025 Q1	$145K	Hold	26,480	–	–	0.03%	131
2024 Q4	$89.8K	Hold	26,480	–	–	0.02%	132
2024 Q3	$75.5K	Hold	26,480	–	–	0.01%	135
2024 Q2	$59.6K	Buy	26,480 +15,000	+131%	+$30.2K	0.01%	132
2024 Q1	$25.4K	Hold	11,480	–	–	﹤0.01%	133
2023 Q4	$27K	Buy	+11,480	New	+$21.2K	0.01%	130

Other funds holding XERS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Asset Management Group's XERS Position: Q2 2026 in Review

Asset Management Group held its Xeris Biopharma Holdings (XERS) position steady in Q2 2026 at 26,480 shares worth $210K. The position accounts for 0.03% of the portfolio, ranked #134.

Asset Management Group first reported a position in XERS in Q4 2023 and has held it in 11 quarters since. The position peaked at $216K in Q3 2025. 241 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

Asset Management Group held 26,480 shares of Xeris Biopharma Holdings worth $210K as of Q2 2026.
Asset Management Group left its Xeris Biopharma Holdings share count unchanged in Q2 2026.
Xeris Biopharma Holdings made up 0.03% of Asset Management Group's portfolio in Q2 2026, its #134 holding.
Asset Management Group first reported a position in Xeris Biopharma Holdings in Q4 2023 and has held it in 11 quarters since.
Asset Management Group's Xeris Biopharma Holdings position peaked at $216K in Q3 2025.
241 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on Asset Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.